May 11, 2017 SYN-004 (Ribaxamase) Receives Breakthrough Therapy Designation from U.S. Food and Drug Administration for Prevention of Clostridium difficile Infection
May 4, 2017 Synthetic Biologics Reports First Quarter 2017 Operational Highlights and Financial Results
April 26, 2017 Synthetic Biologics to Report First Quarter 2017 Operational Highlights and Financial Results on May 4, 2017
April 19, 2017 Synthetic Biologics Reports Preclinical Data Demonstrating SYN-005 Provides Protection from Pertussis in Neonatal Animal Study
February 21, 2017 Synthetic Biologics to Report 2016 Year End Operational Highlights and Financial Results on March 2, 2017
January 18, 2017 Synthetic Biologics Confirms Key Features of Pivotal Phase 2b/3 Trial of SYN-010 Pursuant to Consultations with FDA
January 5, 2017 Synthetic Biologics' SYN-004 (ribaxamase) Achieves Primary Endpoint in Phase 2b Trial for C. difficile Infection (CDI)
